ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags

Kyle LaHucik

Senior Reporter

Back in November, ImmunoGen rallied investors with what looked like a come-from-behind Phase III win. But this morning, the biotech was back to playing defense …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Im­muno­Gen’s ovar­i­an can­cer come­back not as rosy as ex­pect­ed as pro­gres­sion-free sur­vival lags

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

ImmunoGen’s ovarian cancer comeback not as rosy as expected as progression-free survival lags